Orchid Pharma posts 169% year-on-year PAT growth in Q1 FY 2024-25

New Delhi: Orchid Pharma Ltd. has announced financial results for the first quarter of the fiscal year 2024-25, reporting a significant 169% increase in Profit After Tax (PAT) compared to the same period last year. 

The company’s remarkable performance in Q1 reflects its ability to effectively expand its product portfolio and capitalize on market opportunities. Orchid Pharma’s strong market presence has been pivotal in achieving this growth, further cementing its position as a key player in the pharmaceutical industry.

Manish Dhanuka, Managing Director of Orchid Pharma, expressed, “We continue to focus on operational excellence and strategic growth initiatives with a keen eye on project management. We have created a specialized division to combat AMR and our novel drug Enmetazobactam, invented in India drug has put us on a solid footing. It is prudent for me to share that we are all set to launch ORBLICEF, our brand name for the Enmetazobactam + Cefepime combination.”

Dhanuka further noted, “This produce is poised to make a significant impact in the market. Our marketing agreement with CIPLA will further augment its reach. We hope that ORBLICEF will reach a larger audience and achieves its full market potential. Effective project management is critical to our success, ensuring that we meet our timelines, stay within budget, and deliver high-quality outcomes that drive our business forward.”

Orchid Pharma remains dedicated to addressing global healthcare challenges, particularly AMR, through its innovative products and ongoing research efforts. Looking ahead, the company’s growth is supported by a strong product pipeline, strategic investments in research and development, and an expanding global presence.